Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin`s lymphoma. The anticipated time on study treatment is 3 months.
Critère d'inclusion
- Non-Hodgkin's Lymphoma